{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T16:29:00Z","timestamp":1648916940646},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T00:00:00Z","timestamp":1526256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00108-018-0432-3","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T04:48:15Z","timestamp":1526273295000},"page":"519-527","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronische Hepatitis\u00a0B und D (delta)"],"prefix":"10.1007","volume":"59","author":[{"given":"N.","family":"Wortmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"H\u00f6ner zu Siederdissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"432_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","volume":"2","author":"M Bazinet","year":"2017","unstructured":"Bazinet M, P\u00e2ntea V, Vaillant A et al (2017) Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a\u00a0non-randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2:877\u2013889","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"432_CR2","first-page":"S85","volume":"11","author":"M Bazinet","year":"2017","unstructured":"Bazinet M, Placinta G, Moscalu I et al (2017) Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha 2A in treatment naive Caucasian patients with chronic HBeAg negative HBV infection. Hepatol Int. Acta Neurochir (Wien) 11:S85","journal-title":"Acta Neurochir (Wien)"},{"key":"432_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","volume":"65","author":"P Bogomolov","year":"2016","unstructured":"Bogomolov P, Alexandrov A, Urban S et\u00a0al (2016) Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a\u00a0phase Ib\/IIa study. J\u00a0Hepatol 65:490\u2013498","journal-title":"J Hepatol"},{"key":"432_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/liv.13654","volume":"38","author":"F B\u00f6mmel van","year":"2018","unstructured":"van B\u00f6mmel F, Berg T (2018) Stopping long-term treatment with nucleos(t)ide analogues is a\u00a0favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int 38:90\u201396","journal-title":"Liver Int"},{"key":"432_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Marcellin P et al (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a\u00a0randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1:196\u2013206","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"432_CR6","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/jvh.12251","volume":"21","author":"B Calle Serrano","year":"2014","unstructured":"Calle Serrano B, Manns MP, Wedemeyer H et al (2014) Development and evaluation of a\u00a0baseline-event-anticipation score for hepatitis delta. J\u00a0Viral Hepat 21:e154\u2013e163","journal-title":"J Viral Hepat"},{"key":"432_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HLY Chan","year":"2016","unstructured":"Chan HLY, Fung S, Agarwal K et al (2016) Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a\u00a0randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1:185\u2013195","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"432_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.185","author":"M Cornberg","year":"2018","unstructured":"Cornberg M, Manns MP (2018) Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA? Nat Rev Gastroenterol Hepatol. \n                    https:\/\/doi.org\/10.1038\/nrgastro.2017.185\n                    \n                   (\n                    https:\/\/www.nature.com\/articles\/nrgastro.2017.185\n                    \n                  )","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"432_CR9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1055\/s-0031-1273462","volume":"49","author":"M Cornberg","year":"2011","unstructured":"Cornberg M, Protzer U, Manns MP, AWMF (2011) Prophylaxis, diagnosis and therapy of hepatitis B virus infection\u2014the German guideline. Z\u00a0Gastroenterol 49:871\u2013930","journal-title":"Z Gastroenterol"},{"key":"432_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver (2017) European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J\u00a0Hepatol 67:370\u2013398","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"432_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/liv.12749","volume":"35","author":"C Ferrari","year":"2015","unstructured":"Ferrari C (2015) HBV and the immune response. Liver Int 35(Suppl 1):121\u2013128","journal-title":"Liver Int."},{"key":"432_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(17)30315-x","author":"E Gane","year":"2017","unstructured":"Gane E, Gaggar A, Schwabe C et al (2017) A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients. J Hepatol. \n                    https:\/\/doi.org\/10.1016\/s0168-8278(17)30315-x","journal-title":"J. Hepatol."},{"key":"432_CR13","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","volume":"390","author":"GBD 2016 Causes of Death Collaborators","year":"2017","unstructured":"GBD 2016 Causes of Death Collaborators (2017) Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a\u00a0systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1151\u20131210","journal-title":"Lancet"},{"key":"432_CR14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","volume":"60","author":"B Heidrich","year":"2014","unstructured":"HIDIT-1 Study Group, Heidrich B, Manns MP, Wedemeyer H, Wedemeyer H et al. HIDIT-1 Study Group. (2014) Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60:87\u201397","journal-title":"Hepatology"},{"key":"432_CR15","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","volume":"214","author":"C H\u00f6ner Zu Siederdissen","year":"2016","unstructured":"H\u00f6ner Zu Siederdissen C, Maasoumy B, Cornberg M et al (2016) Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J\u00a0Infect Dis 214:1492\u20131497","journal-title":"J Infect Dis"},{"key":"432_CR16","volume-title":"Eiger announces positive phase 2 interim 24-week data with pegylated interferon lambda in hepatitis delta virus (HDV) infection at the American Association for the Study of Liver Diseases (AASLD) meeting","author":"Inc EB","year":"2017","unstructured":"Inc EB (2017) Eiger announces positive phase\u00a02 interim 24-week data with pegylated interferon lambda in hepatitis delta virus (HDV) infection at the American Association for the Study of Liver Diseases (AASLD) meeting. \n                    https:\/\/www.prnewswire.com\/news-releases\/eiger-announces-positive-phase-2-interim-24-week-data-with-pegylated-interferon-lambda-in-hepatitis-delta-virus-hdv-infection-at-the-american-association-for-the-study-of-liver-diseases-aasld-meeting-300540651.html\n                    \n                  . Zugegriffen: 23.3.2018"},{"issue":"Suppl. 1","key":"432_CR17","first-page":"S7","volume":"11","author":"WP Kennedy","year":"2017","unstructured":"Kennedy WP, Weilert FF et al (2017) Safety, tolerability, pharmacokinetics, and antiviral activity of JNJ-56136379, a\u00a0novel HBV capsid assembly modulator, in non-cirrhotic, treatment-na\u00efve patients with chronic hepatitis B. Hepatol Int 11(Suppl. 1):S7\u2013S8","journal-title":"Hepatol Int"},{"key":"432_CR18","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","volume":"15","author":"C Koh","year":"2015","unstructured":"Koh C, Canini L, Heller T et al (2015) Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a\u00a0proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 15:1167\u20131174","journal-title":"Lancet Infect Dis"},{"key":"432_CR19","doi-asserted-by":"publisher","first-page":"122A","DOI":"10.1002\/hep.28659","volume":"64","author":"AC Lee","year":"2016","unstructured":"Lee AC, Reid SP, Thi EP et al (2016) Exploring combination therapy for curing HBV: preclinical studies with capsid inhibitor AB-423 and a\u00a0siRNA agent, ARB-1740. Hepatology 64:122A","journal-title":"Hepatology"},{"key":"432_CR20","first-page":"1269A","volume":"66","author":"S Locarnini","year":"2017","unstructured":"Locarnini S, Wong D, Yuen M\u2011F (2017) Novel antiviral activity of SB 9200 (Inargivir), a\u00a0RIG-1 agonist: results from cohort 1 of the ACHIEVE trial. Hepatology 66:1269A\u20131270A","journal-title":"Hepatology"},{"key":"432_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jhep.2017.10.014","volume":"68","author":"H Mueller","year":"2018","unstructured":"Mueller H, Wildum S, Javanbakht H et\u00a0al (2018) A novel orally available small molecule that inhibits hepatitis B virus expression. J\u00a0Hepatol 68:412\u2013420","journal-title":"J Hepatol"},{"key":"432_CR22","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1128\/AAC.00128-15","volume":"59","author":"E Murakami","year":"2015","unstructured":"Murakami E, Wang T, Ray AS et al (2015) Implications of efficient hepatic delivery by Tenofovir Alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother 59:3563\u20133569","journal-title":"Antimicrob Agents Chemother"},{"key":"432_CR23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/hep.28438","volume":"63","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Vlachogiannakos I, Petersen J et\u00a0al (2016) Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology 63:1481\u20131492","journal-title":"Hepatology"},{"key":"432_CR24","first-page":"348","volume":"13","author":"MG Peters","year":"2017","unstructured":"Peters MG, Locarnini S (2017) New direct-acting antiviral agents and immunomodulators for hepatitis B virus infection. Gastroenterol Hepatol 13:348\u2013356","journal-title":"Gastroenterol Hepatol"},{"key":"432_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cpdd.318","volume":"6","author":"T Schluep","year":"2017","unstructured":"Schluep T, Lickliter J, Given BD et al (2017) Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers. Clin Pharmacol Drug Dev 6:350\u2013362","journal-title":"Clin Pharmacol Drug Dev"},{"key":"432_CR26","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: a\u00a0systematic review of data published between 1965 and 2013. Lancet 386:1546\u20131555","journal-title":"Lancet"},{"key":"432_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Murad MH et\u00a0al (2016) AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63:261\u2013283","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"432_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/liv.13307","volume":"37","author":"B Testoni","year":"2017","unstructured":"Testoni B, Durantel D, Zoulim F (2017) Novel targets for hepatitis B virus therapy. Liver Int 37(Suppl 1):33\u201339","journal-title":"Liver Int."},{"key":"432_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039179","author":"H-T Tzeng","year":"2012","unstructured":"Tzeng H\u2011T, Tsai H\u2011F, Hsu P\u2011N et al (2012) PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a\u00a0mouse animal model. PLoS ONE. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0039179","journal-title":"PLoS ONE"},{"key":"432_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","volume":"147","author":"S Urban","year":"2014","unstructured":"Urban S, Bartenschlager R, Zoulim F (2014) Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147:48\u201364","journal-title":"Gastroenterology"},{"key":"432_CR31","volume-title":"Interim results of a\u00a0multicenter, open-label phase 2b clinical trial to assess the safety and efficacy of Mycrludex B in combination with tenofovir in patients with HBV\/HDV coinfection (Abstract #37, AASLD 2017)","author":"H Wedemeyer","year":"2017","unstructured":"Wedemeyer H, Bogomolov P, Urban S et al (2017) Interim results of a multicenter, open-label phase 2b clinical trial to assess the safety and efficacy of Mycrludex B in combination with tenofovir in patients with HBV\/HDV coinfection (Abstract #37, AASLD 2017)"},{"key":"432_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","volume":"7","author":"H Wedemeyer","year":"2010","unstructured":"Wedemeyer H, Manns MP (2010) Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7:31\u201340","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"432_CR33","first-page":"121A","volume":"64","author":"H Wedemeyer","year":"2016","unstructured":"Wedemeyer H, Port K, Deterding K (2016) A phase 2 study of titrating-dose Lonafarnib plus Ritonavir in patients with chronic hepatitis D: interim results from the Lonafarnib with Ritonavir in HDV-4. Hepatology 64:121A","journal-title":"Hepatology"},{"key":"432_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241","author":"CI Wooddell","year":"2017","unstructured":"Wooddell CI, Yuen M\u2011F, Lewis DL et al (2017) RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a\u00a0source of HBsAg. Sci Transl Med. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aan0241","journal-title":"Sci Transl Med"},{"key":"432_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.coviro.2016.10.002","volume":"20","author":"A Wranke","year":"2016","unstructured":"Wranke A, Wedemeyer H (2016) Antiviral therapy of hepatitis delta virus infection\u2014progress and challenges towards cure. Curr Opin Virol 20:112\u2013118","journal-title":"Curr Opin Virol"},{"key":"432_CR36","volume-title":"Sodium taurocholate cotransporting polypeptide is a\u00a0functional receptor for human hepatitis B and D virus. eLife","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Li W et\u00a0al (2012) Sodium taurocholate cotransporting polypeptide is a\u00a0functional receptor for human hepatitis B and D virus. eLife. \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3485615\/\n                    \n                  . Zugegriffen: 23.03.2018"},{"key":"432_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29658","author":"C Yurdaydin","year":"2018","unstructured":"Yurdaydin C, Keskin O, Glenn JS et al (2018) Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. \n                    https:\/\/doi.org\/10.1002\/hep.29658","journal-title":"Hepatology"},{"key":"432_CR38","series-title":"Subanalysis of the LOWR HDV\u20112 study reveals high response rates to Lonafarnib in patients with low viral loads","first-page":"65","volume-title":"Abstract #\u00a0PS-161","author":"C Yurdaydin","year":"2018","unstructured":"Yurdaydin C, Kalkan C, Karakaya F, Caliskan A, Karatayl\u0131 S, Keskin O et al (2018) Subanalysis of the LOWR HDV\u20112 study reveals high response rates to Lonafarnib in patients with low viral loads. Hepatology 68:65\u2013104. (Abstract #\u00a0PS-161)"},{"key":"432_CR39","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jhep.2017.11.036","volume":"68","author":"F Zoulim","year":"2018","unstructured":"Zoulim F (2018) Inhibition of hepatitis B virus gene expression: a step towards functional cure. J\u00a0Hepatol 68:386\u2013388","journal-title":"J Hepatol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0432-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0432-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0432-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:43:44Z","timestamp":1557794624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0432-3"}},"subtitle":["Gegenw\u00e4rtige und zuk\u00fcnftige Therapien"],"short-title":[],"issued":{"date-parts":[[2018,5,14]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0432-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,14]]},"assertion":[{"value":"14 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Wortmann hat Fortbildungsstipendien von AbbVie erhalten. C.\u00a0H\u00f6ner zu Siederdissen hat Kongressstipendien von Novartis und Gilead erhalten. M.\u00a0Cornberg hat Vortrags- und Beraterhonorare von Roche, Gilead Sciences und Bristol-Myers Squibb erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}